A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer (Prospect)

Clinical Trial ID NCT01322490

PubWeight™ 63.19‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01322490

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014 5.89
2 Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 2011 1.98
3 A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802. Eur Urol 2014 1.44
4 Immunotherapy for the treatment of prostate cancer. Nat Rev Clin Oncol 2011 1.12
5 Overview of the latest treatments for castration-resistant prostate cancer. Nat Rev Urol 2013 1.12
6 Trial watch: DNA vaccines for cancer therapy. Oncoimmunology 2013 1.11
7 Prostate cancer immunotherapy. Clin Cancer Res 2011 1.11
8 Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol 2014 1.11
9 Current status of immunological therapies for prostate cancer. Curr Opin Urol 2010 1.06
10 Molecular pathways and targets in prostate cancer. Oncotarget 2014 1.00
11 Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res 2013 0.99
12 Prostate cancer vaccines: Update on clinical development. Oncoimmunology 2013 0.98
13 The changing landscape in the treatment of metastatic castration-resistant prostate cancer. Ther Adv Med Oncol 2013 0.97
14 Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines. Cancer Immunol Immunother 2011 0.97
15 Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy. Ther Adv Urol 2014 0.96
16 Cancer immunotherapy: a paradigm shift for prostate cancer treatment. Nat Rev Urol 2012 0.93
17 Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Mol Med 2015 0.93
18 Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens. Front Immunol 2014 0.92
19 Serum antibodies to blood group A predict survival on PROSTVAC-VF. Clin Cancer Res 2013 0.92
20 Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy. Curr Opin Oncol 2012 0.92
21 Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going? Viruses 2015 0.92
22 Exploiting synergy: immune-based combinations in the treatment of prostate cancer. Front Oncol 2014 0.91
23 Humoral response to a viral glycan correlates with survival on PROSTVAC-VF. Proc Natl Acad Sci U S A 2014 0.91
24 Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev 2014 0.90
25 Antigen-specific vaccines for cancer treatment. Hum Vaccin Immunother 2014 0.89
26 Update on prostate cancer vaccines. Cancer J 2011 0.88
27 Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int J Mol Sci 2013 0.88
28 Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances. Ther Adv Vaccines 2014 0.86
29 Stereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment. Oncology (Williston Park) 2015 0.85
30 Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning. Oncoimmunology 2014 0.84
31 Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications. Asian J Androl 2014 0.84
32 Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. Cancer J 2013 0.84
33 Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer 2013 0.83
34 Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology 2015 0.83
35 Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era. Ann Oncol 2015 0.82
36 Cross-sectional and longitudinal analysis of cancer vaccination trials registered on the US Clinical Trials Database demonstrates paucity of immunological trial endpoints and decline in registration since 2008. Drug Des Devel Ther 2014 0.82
37 Sequences and combinations of multifaceted therapy in advanced prostate cancer. Curr Opin Oncol 2015 0.82
38 Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination. Hum Vaccin Immunother 2014 0.81
39 Poxviral-based vaccine elicits immunologic responses in prostate cancer patients. Oncoimmunology 2014 0.81
40 Current status of immunological approaches for the treatment of prostate cancer. Curr Opin Urol 2012 0.81
41 Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Ther Adv Med Oncol 2016 0.81
42 Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol (Lausanne) 2012 0.81
43 Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies. Ther Clin Risk Manag 2014 0.80
44 Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy. J Immunother Cancer 2014 0.80
45 Safety and efficacy of cabazitaxel in the docetaxel-treated patients with hormone-refractory prostate cancer. Clin Med Insights Oncol 2012 0.80
46 Beyond sipuleucel-T: immune approaches to treating prostate cancer. Curr Treat Options Oncol 2014 0.79
47 mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer. Hum Vaccin Immunother 2014 0.78
48 Unmet needs in the prediction and detection of metastases in prostate cancer. Oncologist 2013 0.78
49 Initial PSA oscillations precede prolonged stable disease in a patient treated with a therapeutic cancer vaccine. Clin Genitourin Cancer 2011 0.78
50 Drug discovery in advanced prostate cancer: translating biology into therapy. Nat Rev Drug Discov 2016 0.78
51 DNA vaccination for prostate cancer: key concepts and considerations. Cancer Nanotechnol 2015 0.78
52 Immunobiology and immunotherapy in genitourinary malignancies. Ann Transl Med 2016 0.78
53 Visceral metastases and prostate cancer treatment: 'die hard,' 'tough neighborhoods,' or 'evil humors'? Oncology (Williston Park) 2014 0.78
54 Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. Cancer Immunol Res 2016 0.78
55 Immunotherapy for prostate cancer: False promises or true hope? Cancer 2016 0.78
56 Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances. J Natl Compr Canc Netw 2013 0.77
57 Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges. Semin Oncol 2015 0.77
58 Immunotherapy for prostate cancer enters its golden age. Clin Med Insights Oncol 2012 0.77
59 Immune Therapy for Prostate Cancer. Cancer J 2016 0.76
60 Development of PROSTVAC immunotherapy in prostate cancer. Future Oncol 2015 0.76
61 Immunotherapy and immune evasion in prostate cancer. Cancers (Basel) 2013 0.76
62 New clinical advances in immunotherapy for the treatment of solid tumours. Immunology 2015 0.76
63 MyD88/CD40 Genetic Adjuvant Function in Cutaneous Atypical Antigen-Presenting Cells Contributes to DNA Vaccine Immunogenicity. PLoS One 2016 0.75
64 The changing landscape of treatment options for metastatic castrate-resistant prostate cancer: challenges and solutions for physicians and patients. P T 2012 0.75
65 Immunotherapy: shifting the balance of cell-mediated immunity and suppression in human prostate cancer. Cancers (Basel) 2012 0.75
66 A Perspective of Immunotherapy for Prostate Cancer. Cancers (Basel) 2016 0.75
67 Therapeutic cancer vaccines and combination immunotherapies involving vaccination. Immunotargets Ther 2014 0.75
Next 100